Dadaev, T., Saunders, E. J., Newcombe, P. J., Anokian, E., Leongamornlert, D. A., Brook, M. N., Cieza-Borrella, C., Mijuskovic, M., Wakerell, S., Olama, A. A. A., Schumacher, F. R., Berndt, S. I., Benlloch, S., Ahmed, M., Goh, C., Sheng, X.
, Zhang, Z., Muir, K., Govindasami, K. ... PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium (2018).
Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants.
Nature Communications,
9(1), Artikel 2256.
https://doi.org/10.1038/s41467-018-04109-8
Birkenkamp-Demtröder, K., Christensen, E., Sethi, H., Sharma, S., Wu, H.-T.
, Taber, A., Agerbæk, M., Zimmermann, B., Lin, C.-H. J.
, Jensen, J. B. & Dyrskjøt, L. (2018).
Longitudinal Assessment of Multiplex Patient-Specific ctDNA Biomarkers in Bladder Cancer for Diagnosis, Surveillance, and Recurrence. viii26-viii27. Abstract fra IBCN The International Bladder Cancer Network Annual Meeting 2018, Rotterdam, Holland.
Tombal, B.
, Borre, M., Rathenborg, P., Werbrouck, P., Van Poppel, H., Heidenreich, A., Iversen, P., Braeckman, J., Heracek, J., Baron, B., Krivoshik, A., Hirmand, M. & Smith, M. R. (2018).
Long-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Naïve Prostate Cancer: 3-Year Open Label Followup Results.
Journal of Urology,
199(2), 459-464.
https://doi.org/10.1016/j.juro.2017.08.103
van Kessel, K. E. M., van der Keur, K. A.
, Dyrskjøt, L., Algaba, F., Welvaart, N. Y. C., Beukers, W., Segersten, U., Keck, B., Maurer, T., Simic, T., Horstmann, M., Grimm, M.-O., Hermann, G. G., Mogensen, K., Hartmann, A.
, Harving, N., Petersen, A. C., Jensen, J. B., Junker, K. ... Zwarthoff, E. C. (2018).
Molecular Markers Increase Precision of the European Association of Urology Non-Muscle-Invasive Bladder Cancer Progression Risk Groups.
Clinical Cancer Research,
24(7), 1586-1593.
https://doi.org/10.1158/1078-0432.CCR-17-2719